Holen Sie sich die Stockscreener-App
107.39
2.48%
-2.73
Schlusskurs vom Vortag:
$110.12
Offen:
$111.23
24-Stunden-Volumen:
877.95K
Relative Volume:
1.26
Marktkapitalisierung:
$8.93B
Einnahmen:
$51.48M
Nettoeinkommen (Verlust:
$-315.00M
KGV:
-30.07
EPS:
-3.5708
Netto-Cashflow:
$-244.00M
1W Leistung:
-4.07%
1M Leistung:
-9.47%
6M Leistung:
+25.75%
1J Leistung:
+91.77%
1-Tages-Spanne:
$106.53
$111.23
1-Wochen-Bereich:
$106.53
$116.20
52-Wochen-Spanne:
$55.26
$130.05
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Firmenname
Kymera Therapeutics Inc
Sektor
Branche
Telefon
857-285-5314
Adresse
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Compare KYMR vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
107.39 | 9.31B | 51.48M | -315.00M | -244.00M | -3.5708 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-05-06 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-03-16 | Fortgesetzt | Jefferies | Buy |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2026-01-06 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-11-03 | Fortgesetzt | Guggenheim | Buy |
| 2025-10-24 | Bestätigt | B. Riley Securities | Buy |
| 2025-10-21 | Eingeleitet | Mizuho | Outperform |
| 2025-09-18 | Bestätigt | H.C. Wainwright | Buy |
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-09-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-07-30 | Fortgesetzt | B. Riley Securities | Buy |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-06-03 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-05-20 | Fortgesetzt | Stifel | Buy |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2024-12-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-26 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | Eingeleitet | Oppenheimer | Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-01-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | Eingeleitet | Truist | Buy |
| 2023-05-05 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | Eingeleitet | Raymond James | Mkt Perform |
| 2022-08-15 | Eingeleitet | Jefferies | Buy |
| 2022-08-03 | Eingeleitet | Goldman | Buy |
| 2022-07-20 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | JP Morgan | Neutral |
| 2022-02-10 | Eingeleitet | Wells Fargo | Overweight |
| 2021-09-30 | Eingeleitet | B. Riley Securities | Neutral |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-14 | Eingeleitet | Berenberg | Buy |
| 2020-12-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-09-15 | Eingeleitet | BofA Securities | Neutral |
| 2020-09-15 | Eingeleitet | Cowen | Outperform |
| 2020-09-15 | Eingeleitet | Guggenheim | Buy |
| 2020-09-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Kymera Therapeutics Inc Aktie (KYMR) Neueste Nachrichten
B.Riley reiterates Kymera Therapeutics stock rating on new trial data - Investing.com Canada
Kymera Therapeutics stock reports 465.2 percent revenue growth - AD HOC NEWS
JPMorgan Flags Kymera Therapeutics (KYMR) for Positive Catalyst Ahead of Phase 2b Trial Results - GuruFocus
KYMR Stock Clocks Best Day In Over 6 Months On Advancing Eczema Trial Timeline - Stocktwits
Kymera Therapeutics at Stifel forum: faster path for lead drug By Investing.com - Investing.com Australia
Goldman Sachs resumes Kymera Therapeutics stock coverage By Investing.com - Investing.com Australia
Goldman Sachs resumes Kymera Therapeutics stock coverage - Investing.com
KYMR Looks 178.8% Overvalued on GF Value™ - GuruFocus
Piper Sandler reiterates Kymera Therapeutics stock rating at $140 By Investing.com - Investing.com Canada
Kymera Therapeutics doses first participant in KT-485 Phase 1 trial - scanx.trade
KYMR Maintained by Stifel -- Price Target Raised to $152 - GuruFocus
Stifel raises Kymera Therapeutics price target on drug trial outlook By Investing.com - Investing.com Australia
Kymera Therapeutics stock gains as Stifel lifts its target - AD HOC NEWS
Stifel Nicolaus Forecasts Strong Price Appreciation for Kymera Therapeutics (NASDAQ:KYMR) Stock - MarketBeat
Stifel maintains Buy on Kymera Therapeutics, lifts price target to $152 - scanx.trade
Kymera Therapeutics, Inc. (KYMR) Stock Analysis: Unveiling a 17.82% Potential Upside for Biotech Enthusiasts - DirectorsTalk Interviews
(KYMR) Volatility Zones as Tactical Triggers - Stock Traders Daily
Bank of America Corp DE Takes Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics (KYMR) Slips to $117.75 as Shares Consolidate Below Recent ResistanceSkew Index - dars.gov.et
Kymera Therapeutics stock gains as biotech sector strength follows recent earnings - AD HOC NEWS
Kymera Therapeutics stock gains after Morgan Stanley conference highlights oral degrader pipeline - AD HOC NEWS
Kymera Therapeutics, Inc.Common Stock (Nasdaq:KYMR) Price Chart - The Chronicle-Journal
Kymera Therapeutics Is Maintained at Buy by B of A Securities - Moomoo
Kymera's Nello Mainolfi: Degrading Proteins to Beat Dupixent with a Pill - finance.biggo.com
Kymera Therapeutics at Morgan Stanley conference: oral degrader push By Investing.com - Investing.com Canada
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
KYMR Maintained by B of A Securities -- Price Target Raised to $144 - GuruFocus
BofA Securities Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $144 - moomoo.com
BofA raises Kymera Therapeutics price target on trial progress By Investing.com - Investing.com Canada
Understanding Momentum Shifts in (KYMR) - Stock Traders Daily
Kymera Therapeutics at citigroup summit: oral immunology push gains pace By Investing.com - Investing.com Canada
KYMR Upgraded by Wolfe Research -- Rating Raised to Outperform - GuruFocus
Squarepoint Ops LLC Raises Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics at Wells Fargo conference: oral pipeline gains pace By Investing.com - Investing.com South Africa
Kymera Therapeutics at Wells Fargo conference: oral pipeline gains pace - Investing.com
Fund giant T. Rowe Price holds a double-digit stake in Kymera (KYMR) - Stock Titan
Have Kymera Therapeutics Insiders Been Selling Stock? - simplywall.st
36,237 Shares in Kymera Therapeutics, Inc. $KYMR Purchased by Legal & General Group Plc - MarketBeat
Kymera Therapeutics chief legal officer Adams disposes of $744k in KYMR stock - Investing.com Nigeria
Kymera Therapeutics (NASDAQ:KYMR) Insider Brian Adams Sells 6,371 Shares of Stock - MarketBeat
Kymera (NASDAQ: KYMR) insider plans stock sale to cover taxes - Stock Titan
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Atlas Venture Life Science Advisors LLC Decreases Stock Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Can KT-621 Mark a Turning Point for Kymera Therapeutics? - The Globe and Mail
Analysts Conflicted on These Healthcare Names: Kymera Therapeutics (KYMR) and vTv Therapeutics (VTVT) - theglobeandmail.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Braidwell LP Buys 40,604 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat
21,058 Shares in Kymera Therapeutics, Inc. $KYMR Acquired by Jupiter Topco LLC - MarketBeat
Kymera Therapeutics to Participate in Upcoming September Investor Conferences - The Manila Times
Executive at Kymera Therapeutics (NASDAQ: KYMR) plans another stock sale after June trade of $4.4M - Stock Titan
Five September events will webcast Kymera live - Stock Titan
Finanzdaten der Kymera Therapeutics Inc-Aktie (KYMR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Kymera Therapeutics Inc-Aktie (KYMR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mainolfi Nello | Chief Executive Officer |
Oct 01 '26 |
Sale |
113.80 |
30,000 |
3,413,917 |
666,568 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):